Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin

Journal of Hepatology

Volumn 55, Issue 5, 2011, Pages 989-995

  Deltenre, Pierre ^a,b   Corouge, Marion ^a   Canva, Valérie ^a   Castel, Hélne ^a   Wartel, Faustine ^a   Dharancy, Sébastien ^a   Louvet, Alexandre ^a   Lazrek, Mouna ^a   Moreno, Christophe ^c   Henrion, Jean ^b   Mathurin, Philippe ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Hospital de Jolimont   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

Antiviral therapy; Area under the ROC curve; Non responders; Pegylated bitherapy; Relapsers; Stopping rule; Sustained virological response; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD;

ANTIVIRAL AGENTS; AREA UNDER CURVE; DECISION SUPPORT TECHNIQUES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; ROC CURVE; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 80054725317     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.02.014     Document Type: Article

References (20)

1. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171 (Pubitemid 38428955)
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
4. P. Marcellin, N. Boyer, A. Gervais, M. Martinot, M. Pouteau, and C. Castelnau Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann Intern Med 127 1997 875 881
5. R. Sobesky, P. Mathurin, F. Charlotte, J. Moussalli, M. Olivi, M. Vidaud, and The Multivirc Group Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view Gastroenterology 116 1999 378 386 (Pubitemid 29055361)
6. S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnu, and G. Mazzella Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587 (Pubitemid 46453759)
7. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684 (Pubitemid 351664462)
8. S. Deuffic-Burban, P. Deltenre, A. Louvet, V. Canva, S. Dharancy, and A. Hollebecque Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France J Hepatol 49 2008 175 183
9. T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg, and S. Flamm Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
10. D.M. Jensen, P. Marcellin, B. Freilich, P. Andreone, A. Di Bisceglie, and C.E. Brandao-Mello Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial Ann Intern Med 150 2009 528 540
11. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C Hepatology 20 1994 15 20
12. P. Bedossa, T. Poynard, and The METAVIR Cooperative Study Group An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289 293 (Pubitemid 26260021)
13. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, and M. Haaser Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350 (Pubitemid 40439195)
14. M. Friedrich-Rust, M.F. Ong, S. Martens, C. Sarrazin, J. Bojunga, and S. Zeuzem Performance of transient elastography for the staging of liver fibrosis: a meta-analysis Gastroenterology 134 2008 960 974
15. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, and T. Poynard Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 2001 1069 1075 (Pubitemid 32322537)
16. J.A. Swets Measuring the accuracy of diagnostic systems Science 240 1988 1285 1293
17. Zhou X, Obuchowski N, McClish D. Statistical methods in diagnostic medicine. JWa sons, editor. New York: Wiley-Blackwell; 2002.
18. M.W. Fried, S.J. Hadziyannis, M.L. Shiffman, D. Messinger, and S. Zeuzem Rapid virological response in a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection J Hepatol 48 2008 S5
19. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, and V. Carretta Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50 (Pubitemid 351171040)
20. P. Deltenre, V. Canva, M. El Nady, C. Francois, S. Castelain, and S. Dharancy A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study J Viral Hepat 16 2009 500 505